The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Association between Acute Declines in eGFR during Renin-Angiotensin System Inhibition and Risk of Adverse Outcomes
Open accessAbstract
Key Points: Renin-angiotensin system inhibition was favorable for risk of kidney failure (compared with 0% decline with use of placebo or other agents) up to declines in eGFR of 13% over a 3-month period. Relation between eGFR decline after renin-angiotensin system inhibitor initiation and risk of outcomes was stronger in the first 2 years of follow-up and waned over time. Background: Declines in GFR occur commonly when renin-angiotensin system (RAS) inhibitors are started. Our objective was to determine the relation between declines in eGFR during trials of RAS inhibition and kidney outcomes. Methods: We included participants with CKD (eGFR <60 ml/min per 1.73 m 2 ) from 17 trials of RAS inhibition. The exposure was subacute declines in eGFR expressed as % change between randomization and month 3, and in the subset of trials with data available, we also examined % change in eGFR between randomization and month 1. The primary outcome was kidney failure with replacement therapy. Cox proportional hazards models were used to examine the association between subacute declines in eGFR and risk of kidney failure. We used spline models to identify the threshold of change in eGFR below which RAS inhibition was favorable (conservatively comparing a given decline in eGFR with RAS inhibition to no decline in the comparator). Results: A total of 11,800 individuals with mean eGFR 43 (SD 11) ml/min per 1.73 m 2 and median urine albumin-to-creatinine ratio of 362 mg/g (interquartile range, 50–1367) were included, and 1162 (10%) developed kidney failure. The threshold of decline in eGFR that favored the use of RAS inhibitors for kidney failure was estimated to be up to 13% (95% confidence interval, 8% to 17%) over a 3-month interval and up to 21% (95% confidence interval, 15% to 27%) over a 1-month interval after starting RAS inhibitors. Conclusions: In patients treated with RAS inhibitors, ≤13% decline in eGFR over a 3-month period or ≤21% decline over a 1-month period was associated with lower risk of kidney failure compared with no decline in those assigned to placebo or other agents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
KDIGO Clinical Practice Guidelines for Acute Kidney Injury
Khwaja, A. (2012) · Nephron Clinical Practice · doi:10.1159/000339789 · Cited by 8,014 · cited 1×
“8 These declines in eGFR are often of suf fi cient magnitude that they would meet the criteria for AKI or acute kidney disease 9 ; however, because they are thought to be hemodynamic and benign, 10,11 experts recommend tolerating changes in serum creatinine during the initiation of treatment with…”
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493 · cited 1×
“29 Among the subset of trials that ascertained a serum creatinine 1 month after randomization (within a window of 0.3 – 2 months), 3,15-19,”
InfluentialSelf-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Self-citationProportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885 · cited 1×
“31 Because of the presence of nonproportionality ( P , 0.001), we also examined the relation between exposure and outcome over the fi rst 2 years and thereafter separately.”
InfluentialThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
Hebert, L. A., Parikh, S., Prosek, J., Nadasdy, T., & Rovin, B. H. (2013) · American Journal of Nephrology · doi:10.1159/000354390 · Cited by 4,376
Estimating glomerular filtration rate from serum creatinine and cystatin C
Inker, L. A., Schmid, C. H., Tighiouart, H., Eckfeldt, J. H., Feldman, H. I., Greene, T., Kusek, J. W., Manzi, J., Van Lente, F., Zhang, Y. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114248 · Cited by 4,102 · cited 1×
“29 Among the subset of trials that ascertained a serum creatinine 1 month after randomization (within a window of 0.3 – 2 months), 3,15-19,”
InfluentialSelf-citationWright, Jr. (2002) · JAMA · doi:10.1001/jama.288.19.2421 · Cited by 2,043
Self-citation
Cited by
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s011 · Cited by 318
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s011 · Cited by 226
Navaneethan, S. D., Anker, S. D., Filippatos, G. S., Pitt, B., Rossing, P. R., Ruilope, L. M., August, P., BRINKER, M. D., Lage, A. Z., Roberts, L., et al. (2025) · Kidney International · doi:10.1016/j.kint.2025.03.018 · Cited by 25
Advanced chronic kidney disease coexisting with heart failure: navigating patients’ management
Zoccali, C., Levin, A., Mallamaci, F., Giugliano, R. P., & Caterina, R. D. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf128 · Cited by 12
“Early declines in eGFR are common after initiating renin– angiotensin system inhibitors [10 ], ARNIs [11 ], and SGLT-2 inhibitors [12 ], often reflecting hemodynamic changes rather than true kidney injury.”
Kidney Recovery after Acute Kidney Injury: A Comprehensive Review
Vakhshoori, M., Abdipour, A., Bhullar, J., Narayan, M. J., Infante, S., Norouzi, S., & Mathew, R. O. (2025) · Cardiorenal Medicine · doi:10.1159/000546156 · Cited by 9
“…that, among patients treated with renin-angiotensin system inhibitors, an eGFR decline of ≤ 21% over 1 month and ≤ 13% over 3 months was associated with a lower risk of kidney failure compared to control patients treated with a placebo or other medications who experienced no eGFR decline [59].”
Metadata
- Authors
- Ku, E., Tighiouart, H., McCulloch, C. E., Inker, L. A., Adingwupu, O. M., Greene, T., Estacio, R. O., Woodward, M., de Zeeuw, D., Lewis, J. B., Hannedouche, T., Hou, F. F., Jafar, T. H., Imai, E., Remuzzi, G., Heerspink, H. J. L., Toto, R. D., & Sarnak, M. J.
- Affiliations
- University of California, San Francisco (US)
- Tufts University (US)
- Tufts Medical Center (US)
- University of Utah (US)
- Denver Health Medical Center (US)
- The George Institute for Global Health (GB)
- Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
- University Medical Center Groningen (NL)
- ORCID
- Venue
- Journal of the American Society of Nephrology
- Published
- 2024-06-18
- Volume
- 35
- Issue
- 10
- Pages
- 1402-1411
- ISSN
- 1046-6673 (ISSN-L)
- 1533-3450
- PMC
- PMC11452131
- OpenAlex
- W4399767475
- Semantic Scholar
- 1a49314675674d92e8aea5e3fd6ea03c648409d6
- Cited by
- 24
- References
- 39
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 3
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of the American Society of Nephrology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- Funders
- Foundation for the National Institutes of Health (R01 DK121904)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- renin-angiotensin system inhibitors, estimated glomerular filtration rate decline, chronic kidney disease, renal failure, adverse outcomes, threshold analysis, albuminuria, dose-response relationship, ACE inhibitors, angiotensin receptor blockers, risk-benefit assessment
- MeSH terms
- Aged, Angiotensin-Converting Enzyme Inhibitors, Female, Glomerular Filtration Rate, Humans, Male, Middle Aged, Renin-Angiotensin System, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association between Acute Declines in eGFR during Renin-Angiotensin System Inhibition and Risk of Adverse Outcomes. https://app.cochat.ai/papers/10.1681/asn.0000000000000426
- The paper
- Ku, E., Tighiouart, H., McCulloch, C. E., Inker, L. A., Adingwupu, O. M., Greene, T., Estacio, R. O., Woodward, M., de Zeeuw, D., Lewis, J. B., Hannedouche, T., Hou, F. F., Jafar, T. H., Imai, E., Remuzzi, G., Heerspink, H. J. L., Toto, R. D., & Sarnak, M. J. (2024). Association between Acute Declines in eGFR during Renin-Angiotensin System Inhibition and Risk of Adverse Outcomes. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.0000000000000426
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.